Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV type 1 individuals in Denmark, a nation-wide study

AIDS Research and Human Retroviruses

Volumn 27, Issue 12, 2011, Pages 1283-1290

  Audelin, Anne Margrethe ^a   Gerstoft, Jan ^b   Obel, Niels ^b   Mathiesen, Lars ^c   Laursen, Alex ^d   Pedersen, Court ^e   Nielsen, Henrik ^f   Jensen, Janne ^g   Nielsen, Lars ^h   Nielsen, Claus ^a   Jørgensen, Louise Bruun ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g KOLDING HOSPITAL   (Denmark)

^h HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; DENMARK; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DENMARK; DRUG RESISTANCE, VIRAL; FEMALE; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY; PROGNOSIS;

EID: 82455163716     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0368     Document Type: Article

References (30)

1. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospectiv cohort study. Lancet 1999;353(9156):863-868. (Pubitemid 29126872)
2. Metzner KJ, Giulieri SG, Knoepfel SA, et al.: Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009;48(2):239-247.
3. Lohse N, Obel N, Kronborg G, et al.: Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006;11(5): 591-600. (Pubitemid 44277424)
4. Audelin AM, Lohse N, Obel N, Gerstoft J, and Jorgensen LB: The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: A nationwide population-based Danish cohort study 1999-2005. Antiviral Ther 2009;14(7): 995-1000.
5. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, and Sorensen HT: Cohort profile: The Danish HIV Cohort Study. Int J Epidemiol 2009;38(5):1202-1206.
6. Bennett D, Camacho R, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drugresistance: 2009 update. PLoS One 2009;4(3):e4724.
7. Hall T: BioEdit: A user-friendly biological sequence alignment editor and an analysis program for Windows 95/98/ NT. Nucleic Acids Symp Ser 2000;41:95-98.
8. Drummond A, Ashton B, Buxton S, et al.: Geneuios. http:// www.geneious.com/, 2010.
9. Kaye M, Chibo D, and Birch C: Phylogenetic investigation of transmission pathways of drug-resistant HIV-1 utilizing pol sequences derived from resistance genotyping. J Acquir Immune Defic Syndr 2008;49(1):9-16.
10. Cochran WG: Some methods of strengthening the common x2 tests. Biometrics 1954;10:417-451.
11. Armitage P: Tests for linear trends in proportions and frequencies. Biometrics 1955;11:375-386.
12. Jensen-Fangel S, Pedersen L, Pedersen C, et al.: The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002;35(12): 1541-1548. (Pubitemid 36024181)
13. Liu T and Shafer R: Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006;42(11): 1608-1618.
14. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. Plos Med 2008;5(7):1112-1122.
15. Jayaraman G, Archibald C, Kim J, et al.: A population-based approach to determine the prevalence of transmitted drugresistant HIV among recent versus established HIV infections: Results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006;42(1):86-90. (Pubitemid 43947951)
16. Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195(7):951-959. (Pubitemid 46452099)
17. Brenner BG, Roger M, Moisi DD, et al.: Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008;22(18):2509-2515.
18. Jakobsen MR, Tolstrup M, Sogaard OS, et al.: Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome. Clin Infect Dis 2010;50(4):566-573.
19. Wu T, Schiffer C, Gonzales M, et al.: Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003;77(8):4836-4847. (Pubitemid 36402833)
20. Vora S, Marcelin A, Gü nthard H, et al.: Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor- experienced patients. AIDS 2006;20(1):35-40. (Pubitemid 41818112)
21. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Moller A, and Obel N: Trends in the use of highly active antiretroviral therapy in western Denmark 1996-2000. Scand J Infect Dis 2002;34(6):460-465. (Pubitemid 34823443)
22. Yerly S, Rakik A, De Loes SK, et al.: Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998;72(5):3520-3523. (Pubitemid 28188646)
23. Garcia-Lerma J, Nidtha S, Blumoff K, Weinstock H, and Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naïve persons. Proc Natl Acad Sci USA 2001;98(24):13907-13912. (Pubitemid 33115997)
24. Petersen TS, Andersen SE, Gerstoft J, et al.: Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: A Danish nationwide study. Br J Clin Pharmacol 2011. [Accepted].
25. Lohse N, Obel N, Kronborg G, et al.: Declining risk of tripleclass antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005;19(8):815-822. (Pubitemid 40834752)
26. Lindstrom A, Ohlis A, Huigen M, et al.: HIV-1 transmission cluster with M41L singleton mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antiviral Ther 2006;11(8):1031-1039. (Pubitemid 44955179)
27. Taylor S, Cane P, Hué S, et al.: Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003;19(5):353-361. (Pubitemid 36629955)
28. Yerly S, Junier T, Gayet-Ageron A, et al.: The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23(11):1415-1423.
29. Cuevas MT, Munoz-Nieto M, Thomson MM, et al.: HIV-1 transmission cluster with T215D revertant mutation among newly diagnosed patients from the Basque Country, Spain. J Acquir Immune Defic Syndr 2009;51(1):99-103.
30. Buskin SE, Ellis GM, Pepper GG, et al.: Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007. J Acquir Immune Defic Syndr 2008;49(2):205-211